Inner Cosmos offers a minimally invasive, sub‑dermal brain‑computer interface called the “Digital Pill” that continuously monitors neural activity and delivers closed‑loop electrical stimulation to rebalance mood‑related brain networks. The embedded device operates autonomously, enabling remote, cloud‑based personalization of therapy and eliminating the need for frequent clinic visits, with FDA‑cleared trial data showing sustained remission in depression patients.
Funding
$11.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Depression treatment often relies on medication regimens or invasive neuromodulation procedures that can cause side effects, require frequent clinical visits, and may be ineffective for many patients.
Solution
Inner Cosmos has developed a minimally invasive, embedded brain‑computer interface (BCI) termed the “Digital Pill” to treat depression. The device continuously monitors neural activity and delivers targeted stimulation to rebalance brain networks associated with mood regulation. Because the BCI is implanted sub‑dermally and operates autonomously, patients can carry on with daily activities without noticeable interference. Clinical data from an FDA‑approved trial indicate sustained mood improvement and remission over a year of use. The system integrates cloud‑based analytics to personalize stimulation parameters, reducing the need for in‑person appointments and enabling remote therapy management.
Target Audience
Primary customers are individuals with moderate to severe depression who have not responded adequately to conventional treatments, as well as mental‑health providers and clinics seeking non‑invasive neuromodulation options.
Features
- Sub‑dermal BCI that both records neural signals and provides closed‑loop electrical stimulation
- Closed‑loop algorithm that tailors stimulation to individual brain network patterns associated with depression
- Fully embedded, invisible form factor that allows continuous, unobtrusive therapy during normal daily activities
- Remote monitoring and parameter adjustment via secure cloud platform, eliminating routine clinic visits
- FDA‑cleared clinical trial demonstrating one‑year remission rates in participants
- Battery life and wireless charging designed for long‑term, on‑the‑go use